COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN PANAMA

被引：0
|
作者：
Ordonez, J. [1 ]
Valdes, R. [2 ]
Courville, K. [2 ]
Perez, R. [2 ]
Ordonez, A. [3 ]
Hidalgo Godinez, J. [4 ]
Villalobos, K. [4 ]
机构：
[1] True Consulting, Medellin, Colombia
[2] Caja Seguridad Social Panama, Panama City, Panama
[3] True Consulting, Medellin, Colombia
[4] AstraZeneca CAC, San Jose, Costa Rica
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA5
引用
收藏
页码：S504 / S505
页数：2
相关论文
共 50 条
  • [31] Vitamin A supplementation for the prevention of chronic lung disease in premature infants: A cost-utility analysis
    Buendia, Jefferson A.
    Guerrero Patino, Diana
    Fernanda Lindarte, Erika
    PEDIATRIC PULMONOLOGY, 2022, 57 (10) : 2511 - 2517
  • [32] COST-UTILITY ANALYSIS OF COFFEE CONSUMPTION FOR PREVENTION OF CHRONIC DISEASE AND CANCER IN THE UNITED STATES
    O'Day, K.
    Campbell, C. M.
    Popelar, B., V
    VALUE IN HEALTH, 2014, 17 (03) : A91 - A91
  • [33] A COST-UTILITY ANALYSIS ON THE USE OF INDACATEROL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MEXICO
    Garcia-Contreras, F.
    Zuniga, G.
    Briones, B.
    VALUE IN HEALTH, 2011, 14 (03) : A140 - A140
  • [34] Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Akiyama, Mitsuhiro
    Saito, Shutaro
    Kondo, Yasushi
    Azegami, Tatsuhiko
    Kaneko, Yuko
    MODERN RHEUMATOLOGY, 2024,
  • [35] A Cost-Utility Analysis of Smoking Cessation Programs for Patients with Crohn's Disease
    Coward, Stephanie
    Heitman, Steven
    Clement, Fiona
    Negron, Maria
    Panaccione, Remo
    Ghosh, Subrata
    Barkema, Herman
    Seow, Cynthia
    Leung, Yvette
    Kaplan, Gilaad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S525 - S525
  • [36] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
    Patoulias, Dimitrios
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (07)
  • [37] Dapagliflozin versus empagliflozin in patients with chronic kidney disease
    Alnsasra, Hilmi
    Tsaban, Gal
    Solomon, Adam
    Khalil, Fouad
    Aboalhasan, Enis
    Azab, Abed N.
    Azuri, Joseph
    Hammerman, Ariel
    Arbel, Ronen
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
    Chitpim, Natthakan
    Leelahavarong, Pattara
    Prawjaeng, Juthamas
    Ittiphisit, Sakditat
    Srinonprasert, Varalak
    Kongmalai, Tanawan
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [39] Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
    Kamolpat Chaiyakittisopon
    Oraluck Pattanaprateep
    Narisa Ruenroengbun
    Tunlanut Sapankaew
    Atiporn Ingsathit
    Gareth J. Mckay
    John Attia
    Ammarin Thakkinstian
    The European Journal of Health Economics, 2021, 22 : 571 - 584
  • [40] Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis
    Ying, Tracey
    Anh Tran
    Webster, Angela C.
    Klarenbach, Scott W.
    Gill, John
    Chadban, Steven
    Morton, Rachael
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (05) : 693 - 704
12345